Covaxin, the first made-in-India coronavirus vaccine.In the trial results, Bharat Biotech and the ICMR said that Covaxin demonstrates an overall interim clinical efficacy of 78%.
The efficacy against severe Covid-19 disease was 100%, the company said.The second interim analysis is based on accruing more than 87 symptomatic cases of Covid-19.
Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% against mild, moderate, and severe Covid-19 disease, the company said.The efficacy against severe Covid-19 disease was 100%, with an impact on reduction in hospitalisations.